Clinical Physiology, University College London, UK.
University College London, UK.
Lancet Respir Med. 2015 Jan;3(1):33-41. doi: 10.1016/S2213-2600(14)70205-X. Epub 2014 Dec 16.
Morbidity after major surgery is associated with low oxygen delivery. Haemodynamic therapy aimed at increasing oxygen delivery in an effort to reduce oxygen debt, tissue injury, and morbidity, is controversial. The most appropriate target for this strategy is unclear and might have several off-target effects, including loss of neural (parasympathetic)-mediated cellular protection. We hypothesised that individualised oxygen delivery targeted haemodynamic therapy (goal-directed therapy) in high-risk surgical patients would reduce postoperative morbidity, while secondarily addressing whether goal-directed therapy affected parasympathetic function.
In this multicentre, randomised, double-blind, controlled trial, adult patients undergoing major elective surgery were allocated by computer-generated randomisation to a postoperative protocol (fluid, with and without dobutamine) targeted to achieve their individual preoperative oxygen delivery value (goal-directed therapy) or standardised care (control). Patients and staff were masked to the intervention. The primary outcome was absolute risk reduction (ARR) in morbidity (defined by Clavien-Dindo grade II or more) on postoperative day 2. We also assessed a secondary outcome focused on parasympathetic function, using time-domain heart rate variability measures. Analyses were done on an intention-to-treat basis. The trial was registered with Controlled Clinical Trials (number ISRCTN76894700).
We enrolled 204 patients between May 20, 2010, and Feb 12, 2014. Intention-to-treat analysis of the 187 (92%) patients who completed the trial intervention period showed that early morbidity was similar between goal-directed therapy (44 [46%] of 95 patients) and control groups (49 [53%] of 92 patients) (ARR -7%, 95% CI -22 to 7; p=0·30). Prespecified secondary analysis showed that 123 (66%) of 187 patients achieved preoperative oxygen delivery (irrespective of intervention). These patients sustained less morbidity (ARR 19%, 95% CI 3-34; p=0·016), including less infectious complications. Goal-directed therapy reduced parasympathetic activity postoperatively (relative risk 1·33, 95% CI 1·01-1·74).
Achievement of preoperative oxygen delivery values in the postoperative phase was associated with less morbidity, but this was not affected by the use of an oxygen delivery targeted strategy. Reduced parasympathetic activity after goal-directed therapy was associated with the failure of this intervention to reduce postoperative morbidity.
Academy of Medical Sciences and Health Foundation Clinician Scientist Award.
大手术后的发病率与低氧输送有关。旨在增加氧输送以减少氧债、组织损伤和发病率的血流动力学治疗存在争议。这种策略的最合适目标尚不清楚,可能具有多种脱靶效应,包括丧失神经(副交感)介导的细胞保护。我们假设,高危手术患者的个体化氧输送靶向血流动力学治疗(目标导向治疗)将降低术后发病率,同时解决目标导向治疗是否影响副交感功能。
在这项多中心、随机、双盲、对照试验中,接受择期大手术的成年患者通过计算机生成的随机分组分配到术后方案(液体,加用或不加多巴酚丁胺),以达到他们术前的个体氧输送值(目标导向治疗)或标准化护理(对照组)。患者和工作人员对干预措施进行了盲法。主要结局是术后第 2 天发病率的绝对风险降低(ARR)(定义为 Clavien-Dindo 分级 II 级或更高)。我们还评估了一个以副交感功能为重点的次要结局,使用时域心率变异性测量。分析基于意向治疗进行。该试验在控制临床试验(注册号 ISRCTN76894700)中进行了注册。
我们于 2010 年 5 月 20 日至 2014 年 2 月 12 日期间纳入了 204 名患者。对完成试验干预期的 187 名(92%)患者进行意向治疗分析表明,目标导向治疗组(95 名患者中有 44 名[46%])和对照组(92 名患者中有 49 名[53%])的早期发病率相似(ARR-7%,95%CI-22 至 7;p=0·30)。预先指定的次要分析显示,187 名患者中有 123 名(66%)达到了术前氧输送(无论干预措施如何)。这些患者的发病率较低(ARR19%,95%CI3-34;p=0·016),包括感染性并发症减少。目标导向治疗术后降低了副交感神经活动(相对风险 1·33,95%CI1·01-1·74)。
在术后阶段达到术前氧输送值与发病率降低相关,但这与使用氧输送靶向策略无关。目标导向治疗后副交感神经活动减少与该干预措施未能降低术后发病率有关。
医学科学院和健康基金会临床科学家奖。